A multi-centre randomised controlled trial, funded by the NIHR HTA Programme comparing primary medical treatment with primary augmented trabeculectomy (glaucoma surgery) for patients presenting with newly diagnosed advanced glaucoma.
The trial has a primary patient reported outcome, the vision specific health profile (NEI-VF Q25). The primary outcome was evaluated at 24 months.
TAGS closed recruitment in May 2017 with 453 participants recruited.
TAGS follow-up period has been extended to 5 years post-randomisation.
TAGS is led by Professor Anthony King based at Nottingham University Hospital NHS Trust.
For more information please see the TAGS Study Website
- Tracey Davidson; email@example.com